Literature DB >> 33853864

Molecular Subtypes of Pancreatic Cancer: A Proteomics Approach.

Ravi Thakur1, Pankaj K Singh2,3,4,5.   

Abstract

Through molecular subtyping, therapeutic vulnerabilities can be exploited for developing personalized medicine. The real utility of molecular subtyping lies in the clinical translation for disease characterization. Proteomic methods with defined marker sets hold great promise for improving therapy outcomes by improving the speed of predictions for devising treatment strategies.See related article by Son et al., p. 3370. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2021        PMID： 33853864      PMCID： PMC8197741          DOI： 10.1158/1078-0432.CCR-21-0640

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

Review 1.  Molecular subtyping of cancer: current status and moving toward clinical applications.

Authors:  Lan Zhao; Victor H F Lee; Michael K Ng; Hong Yan; Maarten F Bijlsma
Journal:  Brief Bioinform       Date:  2019-03-25       Impact factor: 11.622

2.  Genomic analyses identify molecular subtypes of pancreatic cancer.

Authors:  Peter Bailey; David K Chang; Katia Nones; Amber L Johns; Ann-Marie Patch; Marie-Claude Gingras; David K Miller; Angelika N Christ; Tim J C Bruxner; Michael C Quinn; Craig Nourse; L Charles Murtaugh; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Ehsan Nourbakhsh; Shivangi Wani; Lynn Fink; Oliver Holmes; Venessa Chin; Matthew J Anderson; Stephen Kazakoff; Conrad Leonard; Felicity Newell; Nick Waddell; Scott Wood; Qinying Xu; Peter J Wilson; Nicole Cloonan; Karin S Kassahn; Darrin Taylor; Kelly Quek; Alan Robertson; Lorena Pantano; Laura Mincarelli; Luis N Sanchez; Lisa Evers; Jianmin Wu; Mark Pinese; Mark J Cowley; Marc D Jones; Emily K Colvin; Adnan M Nagrial; Emily S Humphrey; Lorraine A Chantrill; Amanda Mawson; Jeremy Humphris; Angela Chou; Marina Pajic; Christopher J Scarlett; Andreia V Pinho; Marc Giry-Laterriere; Ilse Rooman; Jaswinder S Samra; James G Kench; Jessica A Lovell; Neil D Merrett; Christopher W Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Kim Moran-Jones; Nigel B Jamieson; Janet S Graham; Fraser Duthie; Karin Oien; Jane Hair; Robert Grützmann; Anirban Maitra; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Vincenzo Corbo; Claudio Bassi; Borislav Rusev; Paola Capelli; Roberto Salvia; Giampaolo Tortora; Debabrata Mukhopadhyay; Gloria M Petersen; Donna M Munzy; William E Fisher; Saadia A Karim; James R Eshleman; Ralph H Hruban; Christian Pilarsky; Jennifer P Morton; Owen J Sansom; Aldo Scarpa; Elizabeth A Musgrove; Ulla-Maja Hagbo Bailey; Oliver Hofmann; Robert L Sutherland; David A Wheeler; Anthony J Gill; Richard A Gibbs; John V Pearson; Nicola Waddell; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

Review 3.  Molecular subtypes of pancreatic cancer.

Authors:  Eric A Collisson; Peter Bailey; David K Chang; Andrew V Biankin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-04       Impact factor: 46.802

4.  Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.

Authors:  Francesco Puleo; Rémy Nicolle; Yuna Blum; Jérôme Cros; Laetitia Marisa; Pieter Demetter; Eric Quertinmont; Magali Svrcek; Nabila Elarouci; Juan Iovanna; Denis Franchimont; Laurine Verset; Maria Gomez Galdon; Jacques Devière; Aurélien de Reyniès; Pierre Laurent-Puig; Jean-Luc Van Laethem; Jean-Baptiste Bachet; Raphaël Maréchal
Journal:  Gastroenterology       Date:  2018-08-27       Impact factor: 22.682

5.  Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer.

Authors:  Kamiya Mehla; Pankaj K Singh
Journal:  Clin Cancer Res       Date:  2019-10-18       Impact factor: 12.531

6.  A Clinically Applicable 24-Protein Model for Classifying Risk Subgroups in Pancreatic Ductal Adenocarcinomas using Multiple Reaction Monitoring-Mass Spectrometry.

Authors:  Minsoo Son; Hongbeom Kim; Dohyun Han; Yoseop Kim; Iksoo Huh; Youngmin Han; Seung-Mo Hong; Wooil Kwon; Haeryoung Kim; Jin-Young Jang; Youngsoo Kim
Journal:  Clin Cancer Res       Date:  2021-02-16       Impact factor: 12.531

7.  MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Authors:  Surendra K Shukla; Vinee Purohit; Kamiya Mehla; Venugopal Gunda; Nina V Chaika; Enza Vernucci; Ryan J King; Jaime Abrego; Gennifer D Goode; Aneesha Dasgupta; Alysha L Illies; Teklab Gebregiworgis; Bingbing Dai; Jithesh J Augustine; Divya Murthy; Kuldeep S Attri; Oksana Mashadova; Paul M Grandgenett; Robert Powers; Quan P Ly; Audrey J Lazenby; Jean L Grem; Fang Yu; José M Matés; John M Asara; Jung-Whan Kim; Jordan H Hankins; Colin Weekes; Michael A Hollingsworth; Natalie J Serkova; Aaron R Sasson; Jason B Fleming; Jennifer M Oliveto; Costas A Lyssiotis; Lewis C Cantley; Lyudmyla Berim; Pankaj K Singh
Journal:  Cancer Cell       Date:  2017-07-10       Impact factor: 38.585

8.  Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.

Authors:  Richard A Moffitt; Raoud Marayati; Elizabeth L Flate; Keith E Volmar; S Gabriela Herrera Loeza; Katherine A Hoadley; Naim U Rashid; Lindsay A Williams; Samuel C Eaton; Alexander H Chung; Jadwiga K Smyla; Judy M Anderson; Hong Jin Kim; David J Bentrem; Mark S Talamonti; Christine A Iacobuzio-Donahue; Michael A Hollingsworth; Jen Jen Yeh
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.